OKYO Pharma Ltd. Form 6-K Summary
Business context and reporting period
OKYO Pharma Ltd., a foreign private issuer, furnished a Form 6-K dated March 29, 2023. The filing reports an insider-related purchase of the company’s American depositary securities (ADSs); it does not provide operating or financial results for a reporting period.
Financial metrics and liquidity
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, guidance, or other operating metrics.
Material transaction and changes
- Panetta Partners Limited purchased 12,500 OKYO ADSs on Nasdaq.
- The purchase price was US$1.32 per ADS, implying an aggregate purchase price of US$16,500.
- Gabriele Cerrone, the company’s Executive Chairman, has a beneficial interest in Panetta Partners Limited.
Outlook, risks, and unusual items
The filing contains no management outlook, business update, risk discussion, contingency, or unusual accounting item. Exhibit 99.1 is furnished rather than filed and is not deemed incorporated by reference into other filings unless expressly stated.
Investor verification points
- Verify the beneficial ownership and nature of Gabriele Cerrone’s interest in Panetta Partners Limited.
- Confirm the ADS purchase date, price, and share count against the company’s insider-ownership disclosures.
- Review subsequent filings for any additional insider transactions or changes in executive ownership.
- Consult the company’s annual report and other filings for financial condition, cash runway, debt, and operating performance, which are not addressed here.